2018
Comprehensive Genetic Analysis of Follicular Thyroid Carcinoma Predicts Prognosis Independent of Histology
Nicolson NG, Murtha TD, Dong W, Paulsson JO, Choi J, Barbieri AL, Brown TC, Kunstman JW, Larsson C, Prasad ML, Korah R, Lifton RP, Juhlin CC, Carling T. Comprehensive Genetic Analysis of Follicular Thyroid Carcinoma Predicts Prognosis Independent of Histology. The Journal Of Clinical Endocrinology & Metabolism 2018, 103: 2640-2650. PMID: 29726952, DOI: 10.1210/jc.2018-00277.Peer-Reviewed Original ResearchConceptsFollicular thyroid carcinomaThyroid carcinomaMutation burdenWorse disease-specific survivalDisease-specific survivalDifferent histopathological subtypesWorld Health Organization guidelinesSomatic mutationsNonsynonymous somatic mutationsHealth Organization guidelinesTotal mutation burdenIndependent predictorsWorse prognosisHistopathological subtypesPatient outcomesHistopathological classificationInvasive subtypesClinicopathologic parametersMutational burdenSurvival analysisSomatic copy number alterationsCopy number alterationsSubtypesOrganization guidelinesMore subclones
2017
Metastatic thyroid carcinoma without identifiable primary tumor within the thyroid gland: a retrospective study of a rare phenomenon
Xu B, Scognamiglio T, Cohen PR, Prasad ML, Hasanovic A, Tuttle RM, Katabi N, Ghossein RA. Metastatic thyroid carcinoma without identifiable primary tumor within the thyroid gland: a retrospective study of a rare phenomenon. Human Pathology 2017, 65: 133-139. PMID: 28552827, PMCID: PMC5571865, DOI: 10.1016/j.humpath.2017.05.013.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiomarkers, TumorCarcinomaCarcinoma, PapillaryCell DifferentiationDNA Mutational AnalysisFemaleGenetic Predisposition to DiseaseHumansImmunohistochemistryLymphatic MetastasisMaleMiddle AgedMutationNeoplasm GradingNeoplasms, Unknown PrimaryPhenotypeProto-Oncogene Proteins B-rafRetrospective StudiesThyroid Cancer, PapillaryThyroid Carcinoma, AnaplasticThyroid NeoplasmsConceptsPapillary thyroid carcinomaIdentifiable primary tumorThyroid carcinomaAnaplastic thyroid carcinomaMetastatic diseasePrimary tumorThyroid glandMetastatic papillary thyroid carcinomaEvidence of recurrenceMetastatic nodal diseaseMetastatic thyroid carcinomaTall cell variantBRAF V600E immunohistochemistryThyroid primaryNodal diseaseNeck compartmentDistant metastasisPathologic featuresRetrospective studyAnaplastic carcinomaUnknown causeMost tumorsCarcinomaPatientsThyroid tumors
2016
Trans-oral Vestibular Endocrine Surgery
Udelsman R, Anuwong A, Oprea AD, Rhodes A, Prasad M, Sansone M, Brooks C, Donovan PI, Jannitto C, Carling T. Trans-oral Vestibular Endocrine Surgery. Annals Of Surgery 2016, 264: e13-e16. PMID: 27649533, DOI: 10.1097/sla.0000000000002001.Peer-Reviewed Original ResearchRecurrent Mutations of Chromatin-Remodeling Genes and Kinase Receptors in Pheochromocytomas and Paragangliomas
Toledo RA, Qin Y, Cheng ZM, Gao Q, Iwata S, Silva GM, Prasad M, Ocal IT, Rao S, Aronin N, Barontini M, Bruder J, Reddick RL, Chen Y, Aguiar RC, Dahia PL. Recurrent Mutations of Chromatin-Remodeling Genes and Kinase Receptors in Pheochromocytomas and Paragangliomas. Clinical Cancer Research 2016, 22: 2301-2310. PMID: 26700204, PMCID: PMC4854762, DOI: 10.1158/1078-0432.ccr-15-1841.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdrenal Gland NeoplasmsAdultAgedC-Mer Tyrosine KinaseCarcinoma, NeuroendocrineChildChromatinChromatin Assembly and DisassemblyExomeFemaleGerm-Line MutationGiant Cell Tumor of BoneHistone DemethylasesHistone MethyltransferasesHistone-Lysine N-MethyltransferaseHistonesHumansMaleMiddle AgedParagangliomaPheochromocytomaThyroid NeoplasmsYoung AdultConceptsHistone methylation analysisAnalysis of mutantsChromatin-remodeling genesChromatin remodelingHistone demethylasesTranscriptome sequencingFrequent genetic eventKinase geneMolecular basisPPGL susceptibility genesGenesGenetic eventsNeural crest originMethylation analysisSusceptibility genesNew cancer syndromeMost PPGLsMutationsSomatic mutationsProtein expressionCell linesDomain mutationsFGFR1 mutationsWestern blottingDriver mutations
2015
C-Cell Neoplasia in Asymptomatic Carriers of RET Mutation in Extracellular Cysteine-Rich and Intracellular Tyrosine Kinase Domain
Abi-Raad R, Virk RK, Dinauer CA, Prasad A, Morotti RA, Breuer CK, Sosa JA, Udelsman R, Rivkees SA, Prasad ML. C-Cell Neoplasia in Asymptomatic Carriers of RET Mutation in Extracellular Cysteine-Rich and Intracellular Tyrosine Kinase Domain. Human Pathology 2015, 46: 1121-1128. PMID: 26033033, DOI: 10.1016/j.humpath.2015.04.011.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultCarcinoma, NeuroendocrineChildChild, PreschoolFemaleGenetic Predisposition to DiseaseGerm-Line MutationHeterozygoteHumansInfantMaleMiddle AgedMultiple Endocrine NeoplasiaProtein Structure, TertiaryProto-Oncogene MasProto-Oncogene Proteins c-retThyroid NeoplasmsYoung AdultConceptsMedullary thyroid carcinomaMultiple endocrine neoplasia type 2C-cell hyperplasiaAsymptomatic carriersC-cell neoplasiaRET mutationsMTC familiesHigh-risk RET mutationsIntracellular tyrosine kinase domainTyrosine kinase domainC-cell diseaseC-cell pathologyLymph node metastasisCodon 918 mutationYounger median ageReceptor tyrosine kinase proteinTotal thyroidectomyProgressive diseaseMedian ageNode metastasisThyroid carcinomaType 2Germline mutationsTyrosine kinase proteinFormer group
2014
Morphology predicts BRAFV600E mutation in papillary thyroid carcinoma: an interobserver reproducibility study
Virk RK, Theoharis CG, Prasad A, Chhieng D, Prasad ML. Morphology predicts BRAFV600E mutation in papillary thyroid carcinoma: an interobserver reproducibility study. Virchows Archiv 2014, 464: 435-442. PMID: 24549591, DOI: 10.1007/s00428-014-1552-3.Peer-Reviewed Original Research
2009
IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype
Walter O, Prasad M, Lu S, Quinlan R, Edmiston K, Khan A. IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype. Human Pathology 2009, 40: 1528-1533. PMID: 19695680, DOI: 10.1016/j.humpath.2009.05.005.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorBreast NeoplasmsCarcinoma, Ductal, BreastDisease-Free SurvivalFemaleHumansImmunohistochemistryKaplan-Meier EstimateMiddle AgedNeoplasm ProteinsPhenotypeReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneRetrospective StudiesRNA-Binding ProteinsConceptsHuman epidermal growth factor receptor 2Invasive mammary carcinomaInvasive ductal carcinomaIMP3 expressionNovel biomarkersDuctal carcinomaProgesterone receptorMammary carcinomaBreast cancerEstrogen receptorAggressive phenotypeEpidermal growth factor receptor 2Triple-negative breast cancerDisease-free survivalBiologic prognostic factorsGrowth factor receptor 2Lymph node metastasisInsulin-like growth factor II mRNABasal-like carcinomasGrowth factor II mRNABasal epithelial markersNegative breast cancerBreast cancer casesFactor receptor 2Mouse monoclonal antibodyInsulin-Like Growth Factor mRNA Binding Protein 3 (IMP3) is Differentially Expressed in Benign and Malignant Follicular Patterned Thyroid Tumors
Slosar M, Vohra P, Prasad M, Fischer A, Quinlan R, Khan A. Insulin-Like Growth Factor mRNA Binding Protein 3 (IMP3) is Differentially Expressed in Benign and Malignant Follicular Patterned Thyroid Tumors. Endocrine Pathology 2009, 20: 149-157. PMID: 19449140, DOI: 10.1007/s12022-009-9079-x.Peer-Reviewed Original ResearchConceptsHürthle cell carcinomaPapillary thyroid carcinomaHürthle cell adenomaFollicular carcinomaGraves' diseaseHashimoto's thyroiditisColloid nodulesFollicular adenomaIMP3 expressionThyroid carcinomaStrong stainingInsulin-like growth factor mRNAThyroid lesionsProtein 3Conventional papillary thyroid carcinomaPathologic tumor characteristicsInsulin-like growth factor IIResidual thyroid tissueSurgical pathology archivesBinding protein 3Thyroid follicular lesionsGrowth factor IIGrowth factor mRNATumor characteristicsUterine cervix
2000
Microinvasive Carcinoma (T1mic) of the Breast
Prasad M, Osborne M, Giri D, Hoda S. Microinvasive Carcinoma (T1mic) of the Breast. The American Journal Of Surgical Pathology 2000, 24: 422-428. PMID: 10716157, DOI: 10.1097/00000478-200003000-00012.Peer-Reviewed Original ResearchConceptsDuct carcinomaMicroinvasive carcinomaPositive axillary lymphChest wall recurrenceFoci of invasionHigh-grade nucleiUnderwent lumpectomyAxillary lymphTNM criteriaClinicopathologic dataTubular carcinomaMean ageInvasive fociRadiation therapyAnticytokeratin antibodyEquivocal casesMammographic abnormalitiesPatientsRoutine examinationCarcinomaMuscle actinHistologic slidesMean numberOcular micrometerMICB
1999
Microinvasive carcinoma of the breast: can it be diagnosed reliably and is it clinically significant?
Hoda, Prasad, Moore, Hoda, Giri. Microinvasive carcinoma of the breast: can it be diagnosed reliably and is it clinically significant? Histopathology 1999, 35: 468-470. PMID: 10583563, DOI: 10.1046/j.1365-2559.1999.0820a.x.Commentaries, Editorials and LettersConceptsDefinition of microinvasionPresence of microinvasionSitu breast carcinomaUtility of immunohistochemistryMicroinvasive carcinomaHistological featuresReparative changesBreast carcinomaClinical significanceSitu carcinomaMicroinvasionCarcinomaFurther treatmentCommon problemImmunohistochemistryBreastDiagnosis
1998
Observations on the histopathologic diagnosis of microinvasive carcinoma of the breast.
Prasad M, Osborne M, Hoda S. Observations on the histopathologic diagnosis of microinvasive carcinoma of the breast. Anatomic Pathology 1998, 3: 209-32. PMID: 10389587.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMicroinvasive carcinomaCell infiltrateNuclear gradeSitu carcinomaMalignant cellsMyoepithelial cellsVascular channel involvementInflammatory cell infiltrateFinal pathology reportStatus of marginsUniform diagnostic criteriaInvasive cellsBasement membraneNonneoplastic breast tissueDiagnostic uniformityExcellent prognosisRetrospective studyStromal changesExcised specimenHistologic assessmentPathology reportsHistopathologic diagnosisInvasive fociStromal alterationsTherapeutic decisions